Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

967 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Anti-Apoptotic Effects of Recombinant Human Hepatocyte Growth Factor on Hepatocytes Were Associated with Intrahepatic Hemorrhage Suppression Indicated by the Preservation of Prothrombin Time.
Motoi S, Toyoda H, Obara T, Ohta E, Arita Y, Negishi K, Moriya K, Kuboi Y, Soejima M, Imai T, Ido A, Tsubouchi H, Kawano T. Motoi S, et al. Among authors: obara t. Int J Mol Sci. 2019 Apr 12;20(8):1821. doi: 10.3390/ijms20081821. Int J Mol Sci. 2019. PMID: 31013780 Free PMC article.
Inhibition of the Progression of Skin Inflammation, Fibrosis, and Vascular Injury by Blockade of the CX3 CL1/CX3 CR1 Pathway in Experimental Mouse Models of Systemic Sclerosis.
Luong VH, Utsunomiya A, Chino T, Doanh LH, Matsushita T, Obara T, Kuboi Y, Ishii N, Machinaga A, Ogasawara H, Ikeda W, Kawano T, Imai T, Oyama N, Hasegawa M. Luong VH, et al. Among authors: obara t. Arthritis Rheumatol. 2019 Nov;71(11):1923-1934. doi: 10.1002/art.41009. Epub 2019 Sep 11. Arthritis Rheumatol. 2019. PMID: 31173491
Pharmacokinetics, Pharmacodynamics, and Safety of E6011, a Novel Humanized Antifractalkine (CX3CL1) Monoclonal Antibody: A Randomized, Double-Blind, Placebo-Controlled Single-Ascending-Dose Study.
Tabuchi H, Katsurabara T, Mori M, Aoyama M, Obara T, Yasuda N, Kawano T, Imai T, Ieiri I, Kumagai Y. Tabuchi H, et al. Among authors: obara t. J Clin Pharmacol. 2019 May;59(5):688-701. doi: 10.1002/jcph.1361. Epub 2018 Dec 21. J Clin Pharmacol. 2019. PMID: 30575978 Clinical Trial.
Polymorphisms of fibroblast growth factor receptor 4 have association with the development of prostate cancer and benign prostatic hyperplasia and the progression of prostate cancer in a Japanese population.
Ma Z, Tsuchiya N, Yuasa T, Inoue T, Kumazawa T, Narita S, Horikawa Y, Tsuruta H, Obara T, Saito M, Satoh S, Ogawa O, Habuchi T. Ma Z, et al. Among authors: obara t. Int J Cancer. 2008 Dec 1;123(11):2574-9. doi: 10.1002/ijc.23578. Int J Cancer. 2008. PMID: 18756523
Outcome, clinical prognostic factors and genetic predictors of adverse reactions of intermittent combination chemotherapy with docetaxel, estramustine phosphate and carboplatin for castration-resistant prostate cancer.
Narita S, Tsuchiya N, Yuasa T, Maita S, Obara T, Numakura K, Tsuruta H, Saito M, Inoue T, Horikawa Y, Satoh S, Habuchi T. Narita S, et al. Among authors: obara t. Int J Clin Oncol. 2012 Jun;17(3):204-11. doi: 10.1007/s10147-011-0275-6. Epub 2011 Jun 25. Int J Clin Oncol. 2012. PMID: 21706123 Clinical Trial.
967 results